English | 简体中文 | 繁體中文 | 한국어
Share:
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City

ObsEva SA / ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Geneva, Switzerland and Boston, MA - April 16, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the company will host a key opinion leader (KOL) meeting focused on in vitro fertilization (IVF) Thursday, April 26 from 12:00 to 2:00 p.m. ET in New York City. 

The meeting will feature presentations from David Seifer, M.D., Professor of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, and Annette Lee M.D., Medical Director, Toll Center for Reproductive Sciences, Abington Reproductive Medicine. Additionally, members of the ObsEva management team will provide an overview of the company's oral oxytocin receptor antagonist nolasiban, including recently released positive top line results from the Phase 3 IMPLANT2 clinical trial.

A live webcast of the meeting will be accessible under the "Investors" section of ObsEva's website www.obseva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

###

Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526

CEO Office Contact:
Shauna Dillon
[email protected]
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
857-972-9347 office
781-366-5726 mobile




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
HEINEKEN announces worldwide partnership with Formula E  
Oct 15, 2018 10:30 ET
REC Silicon - Invitation to the third quarter 2018 results  
Oct 15, 2018 10:00 ET
SeaBird Exploration: SeaBird received extension to current OBN survey in US Gulf of Mexico  
Oct 15, 2018 09:00 ET
Klövern AB (publ): Klövern considers issue of hybrid bonds  
Oct 15, 2018 08:30 ET
Amer Sports third quarter 2018 results published on October 25  
Oct 15, 2018 08:00 ET
INGREDION TO RELEASE 2018 THIRD-QUARTER FINANCIAL RESULTS AND HOLD CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 1, 2018  
Oct 11, 2018 22:29 ET
Eastman Schedules Third-Quarter 2018 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast  
Oct 4, 2018 22:29 ET
JCPenney Launches Peyton and Parker,(TM) a New Private Brand Designed for Families and Socially Connected Moms  
Oct 2, 2018 22:29 ET
Lubrizol and Danquinsa Feature High-Performing Bonding Solutions and Non-Yellowing TPUs at Fakuma 2018  
Sept 26, 2018 21:59 ET
INGREDION ANNOUNCES $60 MILLION OF INCREMENTAL PLANNED SPECIALTY CAPITAL INVESTMENTS IN ASIA-PACIFIC; Company's latest move expands its capacity for higher-value specialty ingredients  
Sept 26, 2018 21:29 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: